Cidel Asset Management Inc. Grows Stock Position in CVS Health Corporation $CVS

Cidel Asset Management Inc. grew its stake in CVS Health Corporation (NYSE:CVS) by 16.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,565 shares of the pharmacy operator’s stock after buying an additional 5,467 shares during the quarter. Cidel Asset Management Inc.’s holdings in CVS Health were worth $2,842,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Norges Bank acquired a new position in CVS Health in the fourth quarter valued at approximately $1,666,265,000. Wellington Management Group LLP grew its stake in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after purchasing an additional 12,233,675 shares during the period. Amundi increased its holdings in shares of CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after purchasing an additional 2,253,531 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of CVS Health by 70.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock valued at $399,125,000 after purchasing an additional 2,188,307 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Pharmacy is expanding GLP-1 support across more than 9,000 locations and MinuteClinic, including lower costs, access help, and therapy support, which could boost patient engagement and prescription volume. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: CVS is adding a new $49 virtual MinuteClinic visit and broader weight-management support, reinforcing growth in its consumer health services. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: Traders bought an unusually large number of CVS call options, suggesting bullish sentiment in the stock.
• Positive Sentiment: Third-party research pieces highlighted CVS as a top-ranked value and long-term momentum stock, which may be supporting investor confidence. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Positive Sentiment: CVS also received upbeat coverage for expanding its GLP-1 support, helping explain the stock’s recent outperformance. CVS Health Expands GLP-1 Support for Patients
• Neutral Sentiment: CVS highlighted community and public-health initiatives, including HIV awareness and a grand opening event in New Jersey, but these are unlikely to move the stock materially. CVS Health: Thank You! Mews at St. Mary Grand Opening – Williamstown, NJ
• Neutral Sentiment: Articles noting CVS was “under the microscope” after a healthcare report could keep some regulatory scrutiny in focus, but the details provided do not indicate an immediate financial hit. CVS Health (CVS) Under the Microscope After Recent Healthcare Report

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of NYSE CVS opened at $101.68 on Wednesday. The firm has a market cap of $129.74 billion, a PE ratio of 44.79, a PEG ratio of 0.99 and a beta of 0.62. The firm has a fifty day moving average of $90.21 and a 200 day moving average of $81.86. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a one year low of $58.50 and a one year high of $103.12.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period last year, the firm posted $2.25 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CVS has been the topic of several analyst reports. Robert W. Baird raised their price target on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. UBS Group upped their price objective on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Sanford C. Bernstein increased their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. Argus raised their target price on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Finally, TD Cowen upped their price target on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.28.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.